CORCEPT THERAPEUTICS INC
CORTNASDAQTrading Snapshot
- Day Range
- $86.00 – $88.59
- 52-Week Range
- $28.66 – $126.38
- Volume (shares)
- 1,047,901
- Avg Volume (shares)
- —
- Shares Outstanding
- 108.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $761M
- Last Q Revenue
- $256M
- P/E Ratio
- 173.0
- P/S Ratio
- 11.5x
- EPS (TTM)
- $0.43
- Dividend Yield
- —
- Dilution (1yr)
- +1.2%
CORCEPT THERAPEUTICS INC
CORT
StockOtter · stockotter.spaceAbout CORCEPT THERAPEUTICS INC
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolo
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price o
Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.
First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commi
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.